These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 442176)

  • 1. Symposium on cholera.
    van Heyningen WE
    Trans R Soc Trop Med Hyg; 1979; 73(1):124. PubMed ID: 442176
    [No Abstract]   [Full Text] [Related]  

  • 2. [The immunology of cholera and the molecular biology of cholera toxin. Recent progress and future perspectives].
    Carrada-Bravo T
    Rev Alerg Mex; 1994; 41(3):69-76. PubMed ID: 9377108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An oral B subunit-whole cell vaccine against cholera: from concept to successful field trial.
    Holmgren J; Svennerholm AM; Clemens J; Sack D; Black R; Levine M
    Adv Exp Med Biol; 1987; 216B():1649-60. PubMed ID: 3321938
    [No Abstract]   [Full Text] [Related]  

  • 4. Preparation and evaluation of chitosan nanoparticles containing CtxB antigen against Vibrio cholera.
    Tabrizi NM; Amani J; Ebrahimzadeh M; Nazarian S; Kazemi R; Almasian P
    Microb Pathog; 2018 Nov; 124():170-177. PubMed ID: 30138759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current developments with cholera vaccines: "Where do we go from here?".
    Finkelstein RA
    Prog Clin Biol Res; 1980; 47():133-42. PubMed ID: 7010372
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cholera immunology and the molecular biology of cholera toxin. Recent progress and future prospects].
    Carrada Bravo T
    Rev Alerg; 1993; 40(4):91-4. PubMed ID: 8143024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of the human lymphocyte transformation test to detect a biologically active cholera toxin in Vibrio cholerae culture filtrates].
    Nikolaeva IS; Gaĭlonskaia IN; Ferapontov GK; Astashkin EI
    Vestn Akad Med Nauk SSSR; 1981; (12):62-7. PubMed ID: 7331494
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.
    Levine MM; Nalin DR; Craig JP; Hoover D; Bergquist EJ; Waterman D; Holley HP; Hornick RB; Pierce NP; Libonati JP
    Trans R Soc Trop Med Hyg; 1979; 73(1):3-9. PubMed ID: 442179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral vaccine against cholera prepared from Vibrio cholerae antigen(s).
    Chaicumpa W; Chaisri U; Tapchaisri P; Chongsa-Nguan M; Pongponratn E
    Southeast Asian J Trop Med Public Health; 1987 Jun; 18(2):142-8. PubMed ID: 3313733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic vaccines based on peptides, oligonucleotides and conjugate antigens.
    Arnon R
    Behring Inst Mitt; 1997 Feb; (98):184-90. PubMed ID: 9382739
    [No Abstract]   [Full Text] [Related]  

  • 11. Antigenic and structural variations in the cholera/coli family of enterotoxins.
    Finkelstein RA
    Dev Biol Stand; 1983; 53():93-5. PubMed ID: 6347765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of cholera and rise of novel mucosal vaccine.
    Yamamoto T
    Jpn J Infect Dis; 2000 Oct; 53(5):181-8. PubMed ID: 11135702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synthesis of 15 peptide of the subunit A2(10-24) of cholera toxin and initial biological activity].
    Yuan PN; Dodin A; Le Thuillier G
    Wei Sheng Wu Xue Bao; 1985 Jun; 25(2):146-52. PubMed ID: 3837546
    [No Abstract]   [Full Text] [Related]  

  • 14. Protection against experimental cholera in the rat. A study on the formation of antibodies against cholera toxin and desensitization of adenylate cyclase after immunization with cholera toxin.
    Lange S; Lönnroth I; Nygren H
    Int Arch Allergy Appl Immunol; 1984; 75(2):143-8. PubMed ID: 6469386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Design of a cholera erythrocytic enterotoxic ganglioside indicator for detecting specific immunoglobulins].
    Dolmatova LA; Efremenko VI
    Lab Delo; 1982; (1):40-2. PubMed ID: 6174788
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibodies against Vibrio cholerae lipopolysaccharide, cell-bound haemagglutinin and toxin in the intestinal fluid during convalescence.
    Chongsa-Nguan M; Chaicumpa W; Kalambaheti T; Surachedchai Y; Thanungkul B
    Southeast Asian J Trop Med Public Health; 1987 Mar; 18(1):33-8. PubMed ID: 3660066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local production of anti-vibrio cholerae mucosal antibody in reproductive tract tissues after cholera.
    Ryan ET; Bridges EA; Crean TI; Gausia K; Hamadani JD; Aziz A; Hawkes S; Begum M; Bogaerts J; Faruque SM; Salam MA; Fuchs GJ; Calderwood SB
    J Infect Dis; 2001 Sep; 184(5):643-7. PubMed ID: 11494170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholera studies. IV. Problems in immunology.
    POLLITZER R; BURROWS W
    Bull World Health Organ; 1955; 12(6):945-1107. PubMed ID: 13240451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.
    Xu G; Wang S; Zhuang L; Hackett A; Gu L; Zhang L; Zhang C; Wang H; Huang Z; Lu S
    Vaccine; 2009 Jun; 27(29):3821-30. PubMed ID: 19443090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlled carbon nanotube layers for impedimetric immunosensors: High performance label free detection and quantification of anti-cholera toxin antibody.
    Palomar Q; Gondran C; Holzinger M; Marks R; Cosnier S
    Biosens Bioelectron; 2017 Nov; 97():177-183. PubMed ID: 28599177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.